FDA’s Price Tag For Foreign Facility Inspections Tops $225 Million
Executive Summary
Biennial inspections of all foreign pharmaceuticals facilities would require FDA to spend an additional $225 million per year, according to CDER Director Janet Woodcock
You may also be interested in...
Biosimilars, Generic Programs Leave Little Room For Other New FDA Drug Initiatives In FY ‘13
Proposed and existing user fees would fund 44% of the $4.5 billion FDA FY 2013 spending plan. User fees are projected at $20 million for biosimilars and $229 million for generic drugs.
Globalization Bill Creates Fees For Generic Pre-approval Inspections
A system for assessing fees for generic drug applicants to pay for pre-approval inspections is included in the 1FDA Globalization Act introduced in the House Jan. 28
Globalization Bill Creates Fees For Generic Pre-approval Inspections
A system for assessing fees for generic drug applicants to pay for pre-approval inspections is included in the 1FDA Globalization Act introduced in the House Jan. 28